WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Clinical trials for WARM AUTOIMMUNE HEMOLYTIC ANEMIA explained in plain language.
Never miss a new study
Get alerted when new WARM AUTOIMMUNE HEMOLYTIC ANEMIA trials appear
Sign up with your email to follow new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene-Edited immune cells take on autoimmune blood diseases
Disease control Recruiting nowThis early-stage trial tests a one-time treatment called CTX112, made from donor immune cells edited with CRISPR technology. It aims to safely control two autoimmune diseases where the body attacks its own blood cells: immune thrombocytopenia (ITP) and warm autoimmune hemolytic a…
Matched conditions: WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Second dose of experimental drug may help when first fails
Disease control Recruiting nowThis study tests whether a second course of ianalumab can help adults with two rare blood disorders—immune thrombocytopenia (ITP) and warm-antibody autoimmune hemolytic anemia (wAIHA)—who previously responded to the drug but then stopped responding. About 60 participants will rec…
Matched conditions: WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug rilzabrutinib aims to tame rare blood disorder
Disease control Recruiting nowThis study tests an oral drug called rilzabrutinib for warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. About 90 adults who have not responded well to steroids will receive either rilzabrutinib or a placebo for 24 weeks, follo…
Matched conditions: WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug IASO-782 aims to tame immune attacks on blood cells
Disease control Recruiting nowThis early-stage trial is testing a new drug called IASO-782 in 16 adults with autoimmune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA). These conditions cause the immune system to mistakenly attack blood cells. The study's main goal is to check the drug's sa…
Matched conditions: WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE1 • Sponsor: Shanghai IASO Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody therapy targets stubborn autoimmune blood diseases
Disease control Recruiting nowThis study tests an experimental drug called CM336 in people with relapsed or refractory autoimmune cytopenia, including ITP and autoimmune hemolytic anemia. CM336 is a bispecific antibody designed to target and eliminate certain immune cells. The trial will enroll 158 adults to …
Matched conditions: WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE1, PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC